Yazar "Isikdogan, A." seçeneğine göre listele
Listeleniyor 1 - 20 / 31
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Adjuvant chemoradiotherapy in 450 patients with gastric cancer: The multicenter retrospective study.(Amer Soc Clinical Oncology, 2011) Kucukoner, M.; Isikdogan, A.; Bilici, M.; Tekin, S. B.; Uncu, D.; Cetin, B.; Dane, F.[Abstract Not Available]Öğe Characteristics and prognosis of breast cancer in younger women(Imprimatur Publications, 2009) Dirier, A.; Burhanedtin-Zincircioglu, S.; Karadayi, B.; Isikdogan, A.; Aksu, R.Purpose: Women under 40 years of age comprise a small proportion of patients with breast cancer. Clinical and pathological of disease in these patients are different those in older patients with this type of cancer In the present study we investigated the clinicopathological characteristics and prognostic factors in young patients with breast cancer. Methods: We retrospectively reviewed the medical records of 249 consecutive breast cancer patients who were admitted to our department between August 2001 and December 2005. Clinicopathological features were determined both in patients under and over 40 years of age. Results: 106 (42.5%) patients were tinder and 143 (57.5%) were over 40 years. The mean age was 35.2 years for those under 40 years and 54 for those older than 40 years. At diagnosis, 10.4% of the patients in the younger age group and 7.0% in the older age group had metastasis (p=0.500). Patients in the younger age group exhibited higher estrogen receptor (ER) negativity (48.1 vs. 37.1%) (p=0.425) and a higher percentage of family history of breast cancer (4.7 vs. 2.8%) (p=0.651). Breast cancer in younger women was more frequently associated with other poor prognostic factors such as perineural and/or lymphovascular invasion. The 5-year overall survival was 6.3% for the younger patients and 22.2% for the older ones (p=0.004). Conclusion: This study demonstrates that breast cancer in younger patients has significantly more poor prognostic features compared to older ones.Öğe Childhood, adolescents, and young adults (age 25 and younger) colorectal cancer: A multicenter study(Amer Soc Clinical Oncology, 2011) Kaplan, M. A.; Isikdogan, A.; Gumus, M.; Arslan, U. Yalcintas; Geredeli, C.; Ozdemir, N.; Koca, D.[Abstract Not Available]Öğe Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).(Amer Assoc Cancer Research, 2012) Abulkhair, O.; Uslu, R.; Sezgin, C.; Bueyuekberber, S.; Darwish, T.; Isikdogan, A.; Gumus, M.[Abstract Not Available]Öğe Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer(Elsevier Science Inc, 2018) Akdeniz, N.; Kaplan, M. A.; Urakci, Z.; Kucukoner, M.; Karhan, O.; Isikdogan, A.[Abstract Not Available]Öğe Comparison of three different docetaxel and cisplatin plus fluorouracil (DCF) as first-line therapy for advanced gastric cancer: A retrospective analysis of the two institution(Elsevier Sci Ltd, 2013) Inal, A.; Koca, D.; Kaplan, M. A.; Kucukoner, M.; Urakci, Z.; Dogan, E.; Isikdogan, A.[Abstract Not Available]Öğe Concurrent chemoradiotherapy with or without low molecular weigth heparin (LWMH) in the treatment of locally avanced non-small cell lung cancer (NSCLC)(Amer Soc Clinical Oncology, 2010) Isikdogan, A.; Kaplan, M. A.; Zincircioglu, S. B.; Cit, M.; Cil, T.; Karadayi, B.; Dirier, A.[Abstract Not Available]Öğe Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme(Zerbinis Medical Publ, 2012) Zincircioglu, S. B.; Kaplan, M. A.; Isikdogan, A.; Cil, T.; Karadayi, B.; Dirier, A.; Kucukoner, M.Purpose: Glioblastoma multiforme (GBM) is the most common brain tumor in adults and has a very aggressive course. Median survival is as short as 2 years with standard treatment (chemoradiotherapy followed by adjuvant temozolomide). The purpose of this study was to determine the contribution of low molecular weight heparin (LMWH) addition to concomitant chemoradiotherapy in the treatment of GBM. Methods: All patients with newly diagnosed GBM between March 2004-May 2009 were evaluated. After surgical intervention (total, subtotal resection or only biopsy) all of them were treated with concomitant chemoradiotherapy (2 Gy daily, 5 days a week, 30 fractions, total tumor dose 60 Gy; and 75 mg/m(2) temozolomide, 7 days a week), followed by adjuvant temozolomide (6 cycles, 150-200 mg/m(2), 5 days every 28 days), with or without LMWH (4000 IU/day, 7 days a week, concomitant with radiotherapy) because of risk of thrombosis. The primary endpoint was the determination of progression-free survival (PFS) and overall survival (OS); secondary endpoints were 1- and 2-year OS survival. Results: 30 patients (13 patients in the group non receiving LMWH (LMWH-) and 17 patients in the group receiving LMWH (LMWH+)) were included in the study Median age was 54 years (range 24-75). Median PFS was 57 and 38 weeks in LMWH+ and LMWH- groups, respectively (p=0.068). Median OS was 69 and 44 weeks (p=0.095), 1-year OS survival 84.6 and 41.2% (p=0.016), and 2-year OS survival 38.5 and 5.9% in LMWH+ and LMWH-, respectively (p=0.061). No significant difference was noted between the two groups for grade 3-4 toxicity (p>0.05). Conclusion: Better PFS, OS and 2-year OS survival were obtained in present study with the addition of LMWH to concomitant chemoradiation for GBM but without statistical significance. One-year OS survival was statistically significant favoring the LMWH group. The addition of LMWH did not increase temozolomide toxicityÖğe CONTRIBUTION OF LOW-MOLECULAR WEIGHT HEPARIN ADDITION TO CONCOMITANT CHEMORADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOME MULTIFORME(Oxford Univ Press, 2010) Zincircioglu, S. B.; Kaplan, M. A.; Isikdogan, A.; Cil, T.; Kucukoner, M.; Karadayi, B.; Dirier, A.[Abstract Not Available]Öğe The corelation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma(Amer Soc Clinical Oncology, 2008) Bestas, R.; Isikdogan, A.; Cil, T.; Batun, S.; Altintas, A.[Abstract Not Available]Öğe CRANIAL MAGNETIC RESONANCE IMAGING (MRI) IN THE STAGING OF HER2-POSITIVE BREAST CANCER PATIENTS(Oxford Univ Press, 2012) Kaplan, M. A.; Inal, A.; Kucukoner, M.; Urakci, Z.; Ekici, F.; Firat, U.; Isikdogan, A.[Abstract Not Available]Öğe Docetaxel and Cisplatin Plus Fluorouracil Compared With Modified Docetaxel, Cisplatin, and 5-Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Retrospective Analysis of Single Institution(Aepress Sro, 2012) Inal, A.; Kaplan, M. A.; Kucukoner, M.; Isikdogan, A.Gastric cancer is the second most common among cancer-related deaths in the world. Systemic chemotherapy for patients with gastric cancer has limited impact on overall survival. We performed a retrospective analysis of the efficacy and side effects of Docetaxel and Cisplatin Plus Fluorouracil (DCF) versus Modified-Dose Docetaxel, Cisplatin, and 5-Fluorouracil (mDCF) in the metastatic gastric cancer with first-line chemotherapy treated patients. Retrospectively were reviewed 107 locally advanced or metastatic gastric cancer patients who were treated DCF or mDCF as first-line treatment from June 2007 to August 2011 in Dicle University Hospital, Department of Medical Oncology. The DCF protocol included 75 mg/m(2) docetaxel and cisplatin on day 1 and 750 mg/m2/day 5-FU infusion for 5 days, repeated every 3 weeks. The mDCF protocol included 60 mg/m(2) docetaxel and cisplatin on day 1 and 600 mg/m(2) 5-Fluorouracil continuous infusion per day on days 1-5, every 3 weeks. Patients were treated using DCF arm 85 (M: 56, F: 29), the mDCF arm 22 (M: 13, F: 9) After treatment toxicities were: Grade III-IV neutropenia (48.2% vs 13.6% p=0.003), anemia (21.2% vs 4.5% p=0.06), nausea (44.7% vs 13.6% p=0.008) and vomiting (31.8% vs 4.5%, p=0.01) was higher in the DCF arm. Other toxicities profile was similar in both groups (p>0.05). The rate of response was similar in both arm. Among patients with the DCF and mDCF arm rate complete response (10.3% vs 6.7%, p>0.05), partial response (35.3% vs 40.0%, p>0.05), stable disease (32.4% vs 33.3%, p>0.05), progressive disease (22.1% vs 20.0%, p>0.05) and overal response (45.6% vs 46.7%, p>0.05) did not have a statistically difference (p>0.05). Progression-free survival (PFS) and overall survival (OS) were more favorable in the DCF arm than mDCF arm, but the difference was not significant statistically (9.9 vs 8.6, 7.4 vs 6.5 p>0.05) In conclusion, the response rate, median PFS and median OS are similar in both arms, while the mDCF regimen are more favorable than the DCF for toxicity profile regimen in advanced gastric cancer patients who were undergoing first-line palliative treatment. Therefore, a prospective and larger clinical trials are needed.Öğe Education, economic status and other risk factors in gastric cancer: a case-control study of Turkish oncology group(Humana Press Inc, 2011) Icli, F.; Akbulut, H.; Yalcin, B.; Ozdemir, F.; Isikdogan, A.; Hayran, M.; Unsal, D.Diet and lifestyle related to socioeconomic status emerged as risk factors for gastric cancer in several studies. However, the results were not always consistent with the socioeconomic status. The aim of this study was to evaluate the risk factors independent from education as a measure of socioeconomic status. Two hundred and fifty-three patients with gastric cancer diagnosed in 2005 and equal number of control subjects were interviewed for several characteristics and diet. Matching was done for age, gender, city of residence and also for the level of education. Despite these matching preferences, patients had significantly lower income when compared to the control subjects (P = 0.0001). Higher rate of patients were smoking more than 2 packs/day of cigarettes (P = 0.018). Also significantly higher rate of control subjects were using antibiotics (P = 0.002). Coffee (P < 0.0001), salad (P = 0.006), bread (P = 0.005), vegetable-derived cooking oil (P = 0.003) consumptions appeared as highly protective factors against gastric cancer in univariate analysis in the present trial. In multivariate analysis, significant risk reducing factors were bread (P = 0.005) and coffee consumption (P = 0.0001) other than the level income (P = 0.002). In conclusion, the goal of obtaining comparable socioeconomic status by including the level of education in the matching criteria was not met in our study because of the difference in income level. The only risk reducing factor that was not in accordance with income level was the unexpectedly higher rate of bread consumption in control group.Öğe First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis(Elsevier, 2022) Isikdogan, A.; Turk, H.; Bilir, C.; Sendur, M.; Karabulut, B.; Artac, M.; Cicin, I.[Abstract Not Available]Öğe Gemcitabine alone versus gemcitabine plus cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic adenocarcinoma: A retrospective analysis of multicenter study(Amer Soc Clinical Oncology, 2011) Inal, A.; Isikdogan, A.; Kos, T.; Algin, E.; Gumus, M.; Dikilitas, M.; Elkiran, E. T.[Abstract Not Available]Öğe Hepatitis B and C viruses seroprevalence of cancer patients in southeastern region of Turkey(Pergamon-Elsevier Science Ltd, 2007) Cil, T.; Altintas, A.; Pasa, S.; Kaplan, M.; Isikdogan, A.[Abstract Not Available]Öğe Is Cranial Magnetic Resonance Imaging (MRI) Necessary for Staging of Asymptomatic HER2-Positive Breast Cancer Patients?(Amer Assoc Cancer Research, 2011) Kaplan, M. A.; Inai, A.; Kucukoner, M.; Urakci, Z.; Isikdogan, A.[Abstract Not Available]Öğe Low molecular weight heparin (LMWH) treatment in cancer patients with low risk venous thromboembolism - results of Turkish Observational Study (TREBECA)(Elsevier Sci Ltd, 2015) Ozkan, M.; Cicin, I.; Ozaslan, E.; Benekli, M.; Oksuzoglu, B.; Kocer, M.; Isikdogan, A.[Abstract Not Available]Öğe Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure(Zerbinis Medical Publ, 2011) Alkis, N.; Demirci, U.; Benekli, M.; Yilmaz, U.; Isikdogan, A.; Sevinc, A.; Ozdemir, N. Y.Purpose: To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients. Methods: All patients in this study had previously failed oxaliplatin and irinotecan-based chemotherapy. Patients were treated with MMC (6 mg/m(2) intravenously/i.v) on day 1 in combination with either oral UFT (500 mg/m(2)) and oral leucovorin (LV) (30 mg) on days 1-14 every 3 weeks (group A) or infusional 5-fluorouracil (5-FU) by deGramont regimen with i.v. LV (200 mg/m(2)) on days I and 2, every 2 weeks (group B). Results: Thirty-nine MCRC patients were analyzed. Twenty-two of them were in group A and 17 in group B. Thirty-three were evaluable for clinical efficacy The clinical benefit in the intent-to-treat (ITT) population was 30.8%. Median progression free survival (PFS) was 6 months (95% confidence interval/CI 4-8) and median overall survival (OS) 9 months (95% CI 6.5-11.5). Median PFS was 3 months (95% CI 2.4-3.6) in group A and 7 months (95% CI 5.1-8.9) in group B (p=0.009). Median OS was 7 months (95% CI 4.3-9.7) in group A and 12 months (95% CI 5.4-18.6) in group B (p=0.422). The combination of MMC and fluoropyrimidines was generally well tolerated. The most common severe toxicities were nausea and vomiting, neutropenia, hepatotoxicity and diarrhea. Conclusion: MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients. This combination remains a viable option in these patients. However better therapies are urgently needed.Öğe NT-Probnp levels to perspectively assess acut cardiac failure after adjuvant doxorubicine therapy in early breast cancer patients(Amer Soc Clinical Oncology, 2008) Cil, T.; Altintas, A.; Pasa, S.; Kaplan, M. A.; Alan, S.; Isikdogan, A.[Abstract Not Available]
